​

Apellis Pharmaceuticals (APLS) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Apellis Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$689.38M

Latest Revenue (Q)

$177.75M

Main Segment (Y)

Product

Apellis Pharmaceuticals Revenue by Period

Apellis Pharmaceuticals Revenue by Year

DateRevenueChange
2025-12-31$689.38M-11.77%
2024-12-31$781.37M97.02%
2023-12-31$396.59M425.83%
2022-12-31$75.42M13.31%
2021-12-31$66.56M-73.44%
2020-12-31$250.65M100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31--

Apellis Pharmaceuticals generated $689.38M in revenue during NA 2025, up -11.77% compared to the previous quarter, and up 275.04% compared to the same period a year ago.

Apellis Pharmaceuticals Revenue by Quarter

DateRevenueChange
2025-09-30$177.75M-0.41%
2025-06-30$178.49M7.01%
2025-03-31$166.80M-21.52%
2024-12-31$212.53M7.98%
2024-09-30$196.83M-1.43%
2024-06-30$199.69M15.88%
2024-03-31$172.32M17.73%
2023-12-31$146.38M32.59%
2023-09-30$110.40M16.25%
2023-06-30$94.97M111.77%
2023-03-31$44.85M97.88%
2022-12-31$22.66M2.75%
2022-09-30$22.06M35.13%
2022-06-30$16.32M13.50%
2022-03-31$14.38M-76.15%
2021-12-31$60.29M967.08%
2021-09-30$5.65M806.90%
2021-06-30$623.00K100.00%
2021-03-31--100.00%
2020-12-31$250.00M38599.69%
2020-09-30$646.00K100.00%
2020-06-30-100.00%
2020-03-31--100.00%
2019-12-31$-142.00K100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31--100.00%
2018-12-31$11.54K100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31--100.00%
2017-12-31$11.54K100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2014-12-31-100.00%
2014-09-30--

Apellis Pharmaceuticals generated $177.75M in revenue during Q3 2025, up -0.41% compared to the previous quarter, and up 89.02% compared to the same period a year ago.

Apellis Pharmaceuticals Revenue Breakdown

Apellis Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24Dec 23Dec 22Dec 21
Product$689.38M$709.95M$366.28M$65.09M$15.15M
Licensing And Other Revenue$314.40M$71.41M$30.31M$10.33M$51.42M

Apellis Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (68.68%), and Licensing And Other Revenue (31.32%).

Quarterly Revenue by Product

Product/ServiceDec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
Product$190.34M$177.75M$171.39M$149.90M$191.17M$176.57M$179.14M$163.07M$138.65M$99.18M$89.64M$38.80M$19.65M$17.68M$15.65M$12.11M$9.21M$5.31M
Licensing And Other Revenue$9.57M$280.82M$7.11M$16.90M$21.36M$20.26M$20.55M$9.25M$7.72M$11.22M$5.32M$6.05M$3.01M$4.38M$668.00K$2.27M$51.08M$336.00K

Apellis Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Product (95.21%), and Licensing And Other Revenue (4.79%).

Apellis Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
APLSApellis Pharmaceuticals$689.38M$177.75M
KNSAKiniksa Pharmaceuticals$677.56M$180.85M
CPRXCatalyst Pharmaceuticals$588.99M$146.56M
ADPTAdaptive Bio$276.98M$58.88M
IDYAIDEAYA Biosciences$218.71M$207.83M
RXRXRecursion Pharmaceuticals$74.68M$5.17M
AGIOAgios Pharmaceuticals$54.03M$12.88M
CDTXCidara Therapeutics$1.27M-
MLYSMineralys Therapeutics--
SRRKScholar Rock--
BEAMBeam Therapeutics--

APLS Revenue FAQ

What is Apellis Pharmaceuticals’s yearly revenue?

Apellis Pharmaceuticals's yearly revenue for 2025 was $689.38M, representing a decrease of -11.77% compared to 2024. The company's yearly revenue for 2024 was $781.37M, representing an increase of 97.02% compared to 2023. APLS's yearly revenue for 2023 was $396.59M, representing an increase of 425.83% compared to 2022.

What is Apellis Pharmaceuticals’s quarterly revenue?

Apellis Pharmaceuticals's quarterly revenue for Q3 2025 was $177.76M, a -0.41% decrease from the previous quarter (Q2 2025), and a -9.69% decrease year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $178.49M, a 7.01% increase from the previous quarter (Q1 2025), and a -10.61% decrease year-over-year (Q2 2024). APLS's quarterly revenue for Q1 2025 was $166.8M, a -21.52% decrease from the previous quarter (Q4 2024), and a -3.21% decrease year-over-year (Q1 2024).

What is Apellis Pharmaceuticals’s revenue growth rate?

Apellis Pharmaceuticals's revenue growth rate for the last 3 years (2023-2025) was 73.83%, and for the last 5 years (2021-2025) was 935.68%.

What are Apellis Pharmaceuticals’s revenue streams?

Apellis Pharmaceuticals's revenue streams in c 25 are Product, and Licensing And Other Revenue. Product generated $689.38M in revenue, accounting 68.68% of the company's total revenue, down -2.90% year-over-year. Licensing And Other Revenue generated $314.4M in revenue, accounting 31.32% of the company's total revenue, up 340.25% year-over-year.

What is Apellis Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Apellis Pharmaceuticals was Product. This segment made a revenue of $689.38M, representing 68.68% of the company's total revenue.